PH-PS treatment in 5×FAD Alzheimer's disease mice

Validation Score: 0.900 Price: $0.50 Alzheimer's disease 5×FAD transgenic mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting N/A in 5×FAD transgenic mice. Primary outcome: learning and spatial memory deficits

Description

This comprehensive study investigated the neuroprotective effects of Pseudostellaria heterophylla polysaccharide (PH-PS) in 5×FAD transgenic mice, a well-established animal model of Alzheimer's disease. The experiment examined multiple endpoints including cognitive function, neuropathology, neuroinflammation, and gut microbiome changes. Researchers characterized the PH-PS extract (molecular weight 8.771 kDa, composed of 57.78% glucose, 41.52% galactose, and 0.70% arabinose) and administered it to 5×FAD mice. The study employed behavioral testing to assess learning and spatial memory, histological analysis to evaluate amyloid β plaque burden and glial activation, 16S rRNA sequencing to analyze gut microbiome composition, and molecular analyses to examine inflammatory markers and amyloid-degrading enzymes. The research demonstrated that PH-PS treatment improved cognitive deficits, reduced amyloid pathology, modulated microglial and astrocytic polarization from pro-inflammatory (M1/A1) to anti-inflammatory (M2/A2) phenotypes, restored intestinal barrier function, and promoted beneficial gut bacteria while suppressing harmful inflammatory bacteria.

TARGET GENE
N/A
MODEL SYSTEM
5×FAD transgenic mice
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
amyloid beta clearance, neuroinflammation, gut-brain axis
SOURCE
extracted_from_pmid_38750854
PRIMARY OUTCOME
learning and spatial memory deficits

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

ResearchersindexneuroinflammationmechanismMicrogliaentityMicrobiomeentitiesTREM2 Variants in Alzheimer's DiseasediseaseSporadic vs Familial Alzheimer's Disease: ComprehediseasePSEN2 Mutations in Alzheimer's DiseasediseasePSEN1 Mutations in Alzheimer's DiseasediseaseProdromal Alzheimer's DiseasediseasePreclinical Alzheimer's DiseasediseaseInvestment Landscape: Alzheimer's DiseasediseaseEarly-Onset Alzheimer's Disease (EOAD)diseaseDLB, Parkinson's Disease, and Alzheimer's Disease:diseaseAPP Mutations in Alzheimer's DiseasediseaseAlzheimer's Disease vs Parkinson's Disease Comparidisease

Protocol

Treatment with PH-PS, behavioral testing, histological analysis, 16S rRNA sequencing, cytokine measurement, immunohistochemistry for glial markers and amyloid plaques

Expected Outcomes

Improved cognitive function, reduced amyloid pathology, decreased neuroinflammation, restored gut microbiome balance

Success Criteria

Ameliorated memory deficits, reduced amyloid β build-up, suppressed reactive glia and astrocytes, improved gut microbiota composition

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.